Accueil   Diary - News   All news Poxel Presents Complete PXL770 Phase 1 Results

Poxel Presents Complete PXL770 Phase 1 Results

Poxel Presents Complete PXL770 Phase 1 Results, Cardiac Safety Profile and Preclinical Efficacy Data in NASH at AMPK - From Mechanisms to New Therapies Scientific Congress

 

  • Phase 1 clinical program for PXL770 was observed to have a favorable pharmacokinetic, tolerability and safety profile
  • PXL770 was observed to have a favorable cardiac safety profile in both healthy subjects and in animal models
  • PXL770 was observed to show efficacy in a diet-induced obese-NASH mice model

 

Read the press release